ERBB2 and breast carcinoma: Kirpotin et al. demonstrated that despite no increase in tumour uptake of HER2 targeted liposomes in subcutaneous HER-2 positive breast cancer tumours in vivo, when excised tumours were studied using flow cytometry and microscopy, a 6-fold increase in cell internalisation of these targeted liposomes was observed [36].